Phosphatidic acid (PA), the product of a PLD-mediated reaction, is a lipid second messenger that participates in various intracellular signaling events and is known to regulate a growing list of signaling proteins. We found that Bcl-2 was upregulated by PA treatment in HeLa cells. However, how PA upregulates Bcl-2 expression has not yet been studied. In this study, we tried to discover the mechanisms of 
Introduction
Phosphatidic acid (PA), a lipid second messenger, is the simplest membrane phospholipid that has been implicated in various cellular processes; including signal transduction, membrane trafficking, secretion, and cytoskeletal rearrangement. PA acts as an effective mediator which has been linked to the survival and proliferation of cells and reproduction of organisms. Indeed, exogenous PA has the same mitogenic and biological effects; including growth stimulation of fibroblasts, induction of mRNA for proto-oncogenes, growth factors, activation of the neutrophil NADPH oxidase, and binding to neutrophils (Moolenaar et al., 1986; Siegmann, 1987; Knauss et al., 1990; Perry et al., 1993) . However, the intracellular signaling mechanisms triggered by exogenously added PA are not clear.
PA has been reported to interact with a diversity of signaling molecules such as protein tyrosine kinase, ERK1/2 MAPK and phosphatidylinositol 3 kinase (Ghosh et al., 1996) . ERK1/2 has been involved in the regulation of a variety of cellular processes . Recently, studies have reported that the ERK1/2 signaling pathway regulates the expression of Bcl-2 and Bcl-X L , and promotes the survival of human pancreatic tumor cells (Boucher et al., 2000) . Several MAPK family members including ERK, P38 MAPK, and JNK have been identified as kinases capable of phosphorylating Ser 727 of STAT3 (Gotoh et al., 1996; Chung et al., 1997; Ng and Cantrell, 1997; Lim and Cao, 1999; Turkson et al., 1999; Yokogami et al., 2000) .
Signal transducer and activator of transcription 3 (STAT3) is a key signal molecule for many cyto- kines and growth factor receptors (Heim et al., 1999) and is activated by phosphorylation at Tyr 705 , which induces dimerization, nuclear translocation and DNA binding (Darnell et al., 1994; Ihle, 1995) . Also, STAT3 activation is also regulated by phosphorylation at Ser 727 via the MAPK or mTOR pathway (Wen et al., 1995; Yokogami et al., 2000) . In some studies, the STAT3 signal is mediated in survival for various tumor cell lines. Furthermore, STAT3 activation results in the upregulation of various genes involved in cell survival and proliferation; such as Bcl-2, Bcl-X L Mcl-1, cyclin D, and c-Myc (Zushi et al., 1998; Bromberg et al., 1999; Rahaman et al., 2002) .
In the present study, we investigated the mechanism of Bcl-2 upregulation by PA treatment. We found the effects of PA on Bcl-2 expression and obtained evidence that PA could up-regulate Bcl-2 expression by activation of ERK and phosphorylation of Ser 727 in STAT3 in HeLa cells. These results suggest that PA is also a critical mediator in Bcl-2 up-regulation.
Results

PA increases the expression of Bcl-2 protein
To examine the effect of PA on protein expression of Bcl-2, we treated HeLa cells with various concentrations of PA for 3 h and also treated the cells with 50 μM PA for the indicated time. The expression of Bcl-2 protein reached a maximal level at 50 μM PA for 3 h as shown in Figure 1A and B. Based on these results, we used 50 μM PA for 3 h for optimal conditions of PA treatment with HeLa cells in the whole experiment.
The PA-induced Bcl-2 expression was potentiated by propranolol, a PAP inhibitor, but inhibited by mepacrine, a PLA 2 inhibitor Next, we explored the mechanism of how PA upregulates an anti-apoptotic protein, Bcl-2. PA is converted into lyso-PA (LPA) by PLA2 or DAG by PA-phosphohydrolase (Yon et al., 2003) . Therefore, we checked the effect of propranolol, a well known PAP inhibitor, and mepacrine, a PLA2 inhibitor, on mRNA and protein expression of Bcl-2. As shown in Figure 2A , PA-induced Bcl-2 expression was more greatly increased by pretreatment with propranolol. On the other hand, as shown in Figure  2B , pretreatment with mepacrine blocked PAinduced Bcl-2 mRNA and protein expression. This result suggests that PA-induced Bcl-2 mRNA and protein expression does not pass through the DAG pathway by PAP and that PLA2 is involved in PA-induced Bcl-2 protein and mRNA expression.
DPPA leads to anti-apoptotic Bcl-2 up-regulation
PLA 2 converts PA into AA or LPA (Erickson et al., 1999) . To confirm which of the metabolites of PA The cells were harvested, lysised and subjected to RT-PCR and Western blotting as described in the Methods. The relative quantities of each protein band, normalized to control cells, were quantified using Quantity One software (Bio-Rad).
contribute to the increased Bcl-2 mRNA and protein expression, we treated 1,2-dipalmitoyl-snglycero-3-phosphate (DPPA), PA that has no AA, for the indicated concentrations. We found that DPPA was able to increase the Bcl-2 mRNA and protein expression, as shown in Figure 2C . As a result, LPA, not AA acted as an important metabolite for the Bcl-2 expression.
ERK1/2 MAPK and STAT3 are involved in PA-induced Bcl-2 expression
Exogenous PA has related mitogenic and biological effects. Some studies have reported that PA interacts directly with the serine-threonine kinase Raf-1, an important component of the MAPK signaling cascade (Ghosh et al., 1996) . Recent studies report that Bcl-2 expression is under the regulation of the STAT3 in B-non-Hodgkin's lymphoma (Alas and Bonavida, 2001) . We determined whether treatment with PA relates to ERK1/2 MAPK and STAT3 (Ser 727 ) phosphorylation and Bcl-2 expression in HeLa cells. To confirm whether the PLA2 pathway is crucial in ERK1/2 MAPK and STAT3 (Ser 727 ) phosphorylation or Bcl-2 expression, cells were treated with mepacrine, a PLA2 inhibitor. As a result, upon treatment with mepacrine, phosphorylation of ERK1/2 and STAT3 (Ser 727 ), as well as Effects of a PLA2 inhibitor, mepacrine, and MEK inhibitor, PD98059, on PA-induced ERK1/2, STAT3 (Ser 727 ) phosphorylation, and Bcl-2 expression in HeLa cells. (A) RNA was extracted from cells pretreated with 50 μM mepacrine for 30 min, followed by stimulation with 50 μM PA for 30 min and Bcl-2 mRNA was amplified by RT-PCR. HeLa cells were pretreated with 50 μM mepacrine for 30 min, followed by stimulation with 50 μM PA for 15 min. Cell lysates were analyzed by immunoblotting with anti-ERK1/2, anti-STAT3, and phospho-ERK1/2, phospho-STAT3 (Ser 727 ) antibodies. In the case of Bcl-2 Western blotting, cells were pretreated with 50 μM mepacrine for 30 min, followed by stimulation with 50 μM PA for 3 h. Cell lysates were analyzed by immunoblotting with Bcl-2 antibody. (B) RNA was extracted from cells treated with 50 μM PD98059 for 1 h, followed by stimulation with 50 μM PA for 30 min and Bcl-2 mRNA was amplified by RT-PCR. HeLa cells were pretreated with 50 μM PD98059 for 1 h, followed by stimulation with 50 μM PA for 15 min. Cell lysates were analyzed by immunoblotting with anti-ERK1/2, STAT3, and phospho-ERK1/2, STAT3 (Ser 727 ) antibodies. In the case of Bcl-2 Western blotting, cells were pretreated with 50 μM PD98059 for 1 h, followed by stimulation with 50 μM PA for 3 h. Cell lysates were analyzed by immunoblotting with Bcl-2 antibody. The relative quantities of each protein band, normalized to control cells, were quantified using Quantity One software (Bio-Rad).
Bcl-2 expression after PA-stimulation, were partially reduced as shown in Figure 3A . Next we investigated whether ERK1/2 regulates PA-induced Bcl-2 expression and phosphotylation of STAT3 (Ser 727 ) using PD98059, an ERK1/2 inhibitor in HeLa cells. ERK1/2 inhibitor, PD98059, inhibits the phosphorylation of STAT3 (Ser 727 ) and PA-induced Bcl-2 expression, as shown in Figure 3B . These results suggest that ERK1/2 and STAT3 are located downstream of PLA 2 .
Treatment of STAT3 siRNA reduces STAT3 expression and PA-induced Bcl-2 expression To determine whether STAT3 (Ser 727 ) could mediate the effect of PA-induced Bcl-2 expression we treated HeLa cells with STAT3 siRNA to knockdown STAT3 expression. Scrambled siRNA was transfected as a control. As shown in Figure 4 , STAT3 siRNA decreased PA-induced Bcl-2 expression as well as expression and Ser 727 phosphorylation of STAT3 to control levels. This result su- pports that STAT3 (Ser 727 ) is directly related to PA-induced Bcl-2 expression.
Discussion
Bcl-2, a proto-oncogene, was first identified as an oncoprotein coded by a gene translocation of chromosomes 14:18 and induced in follicular B-cell lymphomas (Tsujimoto et al., 1985) . Bcl-2 prevents IL-3-dependent cells from apoptotic death upon withdrawal of the cytokine (Vaux et al., 1988) . Members of the Bcl-2 family are classified as antiapoptotic factors, which include Bcl-2, Bcl-xL, Mcl-1, and others. The proapoptotic members can be separated into two subgroups: the Bax subfamily (Bax, Bak and Bok), which contain multiple BH domains, and the BH3-only family including Bad, Bid, Bim, Noxa, Hrk, and others (Huang and Strasser, 2000; Adams and Cory, 2001; Newmeyer and Ferguson-Miller, 2003; Tsujimoto, 2003; Choi et al., 2006) . Bcl-2 protein is the most important regulator of apoptosis and is involved in the regulation of the cell cycle (O'Reilly et al., 1997) , prolongs cell survival (Korsmeyer, 1992) , and inhibits apoptosis (O'Reilly et al., 1997) . Several studies have reported that Bcl-2 modulates cell differentiation (Lu et al., 1995) and gene expression (Miyashita et al., 1995) and also regulates the transactivity of several transcription factors such as NF-κB (Ricca et al., 2000) , and p53 (Froesch et al., 199) . Furthermore Bcl-2 regulates outer mitochondrial membrane permeability and release of cytochrome C and other apoptogenic factors (Huang and Strasser, 2000; Adams and Cory, 2001; Newmeyer and Ferguson-Miller, 2003; Tsujimoto, 2003; Choi et al., 2006) . Previously, we reported that PA produced by PLD raises Bcl-2 protein expression in several cells lines (Oh et al., 2007; Cho et al., 2008) . However, how PA regulates Bcl-2 expression has not been studied yet.
When we treated HeLa cells with PA, Bcl-2 expression was increased in both a dose-and timedependent manner. However PA did not show any effect on the expression of another antiapoptotic protein, such as Bcl-xL (data not shown). PA can be degraded into arachidonic acid (AA) and lyso-PA (LPA) by PLA 2 . AA, a polyunsaturated fatty acid, can be converted to prostaglandin by cyclooxygenase (COX) (Herrmann et al., 1997) . To find out whether PLA 2 , a product of PA, was involved in the increased expression of Bcl-2 in HeLa cells, we used DPPA, which has two palmitic acids instead of AA. DPPA treatment also increased Bcl-2 expression, indicating that LPA, not AA, is an important mediator in down stream of PA for the induction of Bcl-2 expression.
Recently, the MAPK cascade, which is well known for cell proliferation and differentiation including cell signaling, were studied to be associated with the apoptotic pathway . Ghosh et al. (1996) first proposed that PA is a regulator of the ERK phosphorylation cascade. ERK, P38 MAPK, and JNK have been identified as kinases capable of phosphorylationg serine 727 of STAT3 (Gotoh et al., 1996; Chung et al., 1997; Ng and Cantrell, 1997; Lim and Cao, 1999; Turkson et al., 1999; Yokogami et al., 2000) . Indeed, the transcriptional activity of STAT3 via Ser 727 phosphorylation was modulated by ERK (Chung et al., 1997) . Interestingly, STAT3 is an important transcription factor for the regulation of Bcl-2 gene expression in B-nonHodgkin's lymphoma (Alas and Bonavida, 2001 ). To establish the relationship between PA and ERK1/2/STAT3 (Ser 727 ), we examined whether the ERK1/2 and STAT3 (Ser 727 ) were activated by PA. We found that activation of ERK1/2 and STAT3 (Ser 727 ) through PA treatment are completely abolished by pretreatment with mepacrine, a PLA 2 inhibitor. The inhibition of MEK1/2 by PD98059 also led to the suppression of PA-induced Bcl-2 expression and phosphorylation of STAT3 (Ser 727 ). We further investigated the involvement of STAT3 (Ser 727 ) in Bcl-2 up-regulation by using STAT3 siRNA. As expected, knockdown of STAT3 showed a decrease in PA-induced Bcl-2 expression. These results strongly suggest that activation of ERK1/2 and STAT3 (Ser 727 ) were closely related to the PA-induced Bcl-2 expression pathway.
Taken together, results in the present study indicate that PA acts as an important regulator during Bcl-2 up-regulation in HeLa cells. On top of this result, LPA is also responsible for increasing PAinduced Bcl-2 expression in HeLa cells through activating ERK1/2 and STAT3.
Methods
Materials
FBS, penicillin/streptomycin solution, and DMEM with L-glutamine and low glucose were purchased from Gibco-BRL (MD). Bcl-2 monoclonal antibody and GAPDH polyclonal antibody were obtained from Santa Cruz Biotechnology (CA). ERK1/2 polyclonal antibody and p-ERK1/2 monoclonal antibody, STAT3 polyclonal antibody and p-STAT3 (Ser 727 ) polyclonal antibody were obtained from Cell signaling (MA). Propranolol and mepacrine were purchased from Sigma-Aldrich (MO). 1,2-dipalmitoyl-sn-glycero-3-phosphate (DPPA) was purchased from Avanti Polar Lipids (Alabaster, AL). 1,2-dioctanoly-sn-glycerol-3-phosphate sodium salt (PA) was purchased from Sigma-Aldrich (MO). PD98059 was purchased from Calbiochem (CA).
Cell culture
HeLa cells were incubated for 2 days at 37 o C in DMEM supplemented with 10% (v/v) heated-inactivated FBS, 100 units/ml penicillin, and 100 μg/ml streptomycin. Cells were grown at 37 o C in a humidified CO2-controlled (5%) incubator, then washed with DMEM medium containing 0.1% (w/v) BSA, 100 units/ml penicillin, and 100 μg/ml streptomycin (serum-free medium) and incubated in a serum-free medium at 37 o C for 18 h before treatment.
Reverse transcriptase polymerase chain reaction (RT-PCR)
cDNA was made from total mRNA extracted from cells. Total cellular RNA was isolated using Trizol reagent (Life Technologies Inc., Rockville, MD) according to the manufacturer's instructions. For the reverse transcriptase reaction, 5 μg of total RNA was mixed with oligo (dT)16 primer and Maloney murine leukemia virus (M-MLV) reverse transcriptase (Promega, Madison, WI), and the mixture was incubated for 60 min at 42 o C. The transcribed products were mixed with each primer set and Taq DNA polymerase (Takara Shuzo, Japan), and then amplified. Bcl-2 sense 5'-CATTTCCACGTCAACAGAATTG-3' and antisense 5'-AGCACAGGATTGGATATTCCAT-3 (PCR product, 505bp)': GAPDH sense: 5'-GCTCAGACACCATGG -GGAAGGT-3' and antisense: 5'-GTGGTGCAGGAGGCAT-TGCTGA (PCR product, 473 bp). The PCR products were analyzed in 1.2% agarose-gel.
Western blot analysis
Cells were washed twice with ice-cold PBS and scraped in PBS, then harvested by microcentrifugation. The cells were then resuspended in 0.5 ml of lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NAF, 1 mM Na3VO4, 1 mM PMSF, 1% Triton X-100, 0.5% NP-40, 10 μg/ml aprotinin, 10 μg/ml leupeptin) on ice and disrupted by sonication. Cell lysates were centrifuged for 10 min at 10,000 ×g at 4 o C. Proteins (30 μg of protein/ lane) from control or treated cells were resolved by SDS-PAGE and transferred to nitrocellulose membranes using a Bio-Rad semi-dry transfer system. The membranes were blocked for 1 h with 5% (v/v) non-fat milk in TTBS (trisbuffered saline containing 0.1% Tween 20) and then incubated with diluted specific antibody (1 μg/ml) for another hour. Unbound primary antibodies were removed by three washes (5 min each) with TTBS. The membranes were then incubated with HRP-coupled goat anti-rabbit or antimouse IgG (diluted 1:1000 with TTBS; KPL, Gaithersburg, MD) for 1 h, followed by three washes (5 min each) in TTBS. Visualization of signals was achieved by using chemiluminescence (ECL reagent, Amersham Biosciences) according to the manufacturer's protocol. Protein concentrations were routinely determined by the Bradford procedure with Bio-Rad dye reagent and BSA as a standard.
Small interference RNA (siRNA) synthesis and transfection
Human STAT3 siRNA was purchased from Ambion (Austin, TX). A human STAT3 sequence (sense: 5'-AACUUC-AGACCCGUCAACAAAdTdT-3'; antisense 5'-UUUGUUGACGGGUCUGAAGUUdTdT-3') was chosen for STAT3 RNAi targeting. The siRNA was transiently transfected into the HeLa cell (3 × 10 5 cells/well; 6-well plate) using the NeoFX reagent and 72 h after tranfection, the cells were harvested for Western blotting. A negative control was carried out with Negative Control siRNA#2 (from Ambion).
Statistical analysis
All experiments were performed at least three times in triplicate, and results were expressed as mean value of ± SD. The significance of differences were assessed by an unpaired t-test.
